NHS Dudley Health Economy Medicines Formulary
Home > 5 Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis > 5.3.3.2 Chronic hepatitis C > Daclatasvir for treating chronic hepatitis C - NICE TAG TA364

Daclatasvir for treating chronic hepatitis C - NICE TAG TA364

1.1 Daclatasvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1, only if the company provides daclatasvir at the same price or lower than that agreed with the Commercial Medicines Unit.

Table 1 Daclatasvir for treating adults with chronic hepatitis C

HCV genotype, liver disease stage

Treatment

Duration (weeks)

Recommendation according to treatment history

Untreated

Treated

Interferon‑ineligible or intolerant

1, without cirrhosis

Daclatasvir + sofosbuvir

12

Recommended only if the person has significant fibrosis

Recommended only if the person has significant fibrosis

Recommended only if the person has significant fibrosis

4, without cirrhosis

Daclatasvir + sofosbuvir

12

Not recommended

Recommended only if the person has significant fibrosis

Recommended only if the person has significant fibrosis

1 or 4, with compensated cirrhosis

Daclatasvir + sofosbuvir (with or without ribavirin)

24

Not recommended

Not recommended

Recommended

3, without cirrhosis

Daclatasvir + sofosbuvir

12

Not recommended

Not recommended

Recommended only if the person has significant fibrosis

3, with compensated cirrhosis

Daclatasvir + sofosbuvir + ribavirin

24

Not recommended

Not recommended

Recommended

4

Daclatasvir + peginterferon alfa + ribavirin

24

Recommended only if the person has significant fibrosis or compensated cirrhosis

Recommended only if the person has significant fibrosis or compensated cirrhosis

Not applicable

Abbreviation: HCV, hepatitis C virus.

Significant fibrosis is defined as METAVIR fibrosis stages F3 and F4.

Treated – the person's hepatitis C has not adequately responded to interferon‑based treatment.

1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

1.3 People whose treatment with daclatasvir is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta364

Site by Devopa
© Copyright 2020 NHS. All rights reserved.